Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Yoon, Jae-Ho  [Clear All Filters]
Journal Article
Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Eom K-S, Kim Y-J. Acute colonic pseudo-obstruction following allogeneic stem cell transplantation successfully treated by neostigmine. Blood Res. 2013;48(2):145-8.
Lee S-E, Lim J-Y, Bin Ryu D-, Kim TWoo, Park SSoo, Jeon Y-W, Yoon J-H, Cho B-S, Eom K-S, Kim Y-J, et al. Alteration of the intestinal microbiota by broad-spectrum antibiotic use correlates with the occurrence of intestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2019.
Lee S-E, Yoon J-H, Shin S-H, Eom K-S, Kim Y-J, Kim H-J, Lee S, Cho S-G, Lee JWook, Min W-S, et al. Bone Marrow Plasma Cell Assessment before Peripheral Blood Stem Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biomed Res Int. 2014;2014:982504.
Eom K-S, Shin S-H, Yoon J-H, Yahng S-A, Lee S-E, Cho B-S, Kim Y-J, Kim H-J, Min C-K, Kim D-W, et al. Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission. Am J Hematol. 2013.
Cho B-S, Yahng S-A, Min G-J, Park S, Park S-S, Shin S-H, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, et al. Comparable outcomes after alternative and matched sibling donor hematopoietic stem cell transplantation and the role of molecular measurable residual disease for acute myeloid leukemia in elderly patients. Transplant Cell Ther. 2021.
Park S, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, Shin S-H, Yoon J-H, Lee S-E, Cho BSik, Eom K-S, et al. Comparison of myeloablative (CyTBI, BuCy) versus reduced-intensity (FluBu2TBI400) peripheral blood stem cell transplantation in acute myeloid leukemia patients with pre-transplant low WT1 expression. Biol Blood Marrow Transplant. 2020.
Yoon J-H, Lee S. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy. Korean J Intern Med. 2024;39(1):34-56.
Jeon Y, Kim T-Y, Min GJune, Park S-S, Park S, Yoon J-H, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, et al. Efficacy of ex vivo purging with CD34+ selection to maximize the effects of autologous stem cell transplantation in peripheral T-cell lymphoma patients. Cytotherapy. 2023.
Lim JUk, Park S, Yoon J-H, Lee S-E, Cho B-S, Kim Y-J, Lee S, Kim H-J, Rhee CKook. Efficacy of inhaled tiotropium add-on to budesonide/formoterol in patients with bronchiolitis obliterans developing after hematopoietic stem cell transplantation. Respir Med. 2023:107410.
Park S-S, Jeon Y-W, Min GJune, Park S, Yahng S-A, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, et al. Graft-versus-host disease free, relapse-free survival after allogeneic stem cell transplantation for myelodysplastic syndrome. Biol Blood Marrow Transplant. 2018.
Yoon J-H, Choi CWon, Won J-H. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea. Korean J Intern Med. 2021.
Cho B-S, Jeon Y-W, Hahn A-R, Lee T-H, Park S-S, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, Lee S, et al. Improved survival outcomes and restoration of graft-vs-leukemia effect by deferasirox after allogeneic stem cell transplantation in acute myeloid leukemia. Cancer Med. 2019.
Shin S-H, Park S-S, Park S, Jeon Y-W, Yoon J-H, Yahng S-A, Cho B-S, Kim Y-J, Lee S, Kim H-J, et al. Nonmyeloablative matched sibling stem cell transplantation with the optional reinforced stem cell infusion for patients with hemoglobinopathies. Eur J Haematol. 2020.
Yoon J-H, Kim H-J, Shin S-H, Yahng S-A, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Normal karyotype mosaicism in adult AML patients with adverse-risk and undefined karyotype: preliminary report of treatment outcomes after hematopoietic stem cell transplantation. Int J Hematol. 2013.
Yoon J-H, Kim H-J, Jeon Y-W, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, et al. Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations. Genes Chromosomes Cancer. 2015.
Lee S-E, Min GJune, Park S-S, Park S, Yoon J-H, Shin SHwan, Cho B-S, Eom K-S, Kim Y-J, Lee S, et al. Outcomes of haploidentical stem cell transplantation using total body irradiation (600 cGy) and fludarabine with ATG in adult patients with severe aplastic anemia: A prospective phase II study. Biol Blood Marrow Transplant. 2020.
Jeon Y-W, O J-H, Park K-S, Min GJune, Park S-S, Yoon J-H, Eom K-S, Min C-K, Cho S-G. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP. Br J Haematol. 2019.
Park S, Bang S-Y, Kwag D, Lee JHyuk, Kim TYoon, Lee J, Min GJune, Park SSoo, Yahng S-A, Jeon Y-W, et al. Reduced toxicity (FluBu3) versus myeloablative (BuCy) conditioning in acute myeloid leukemia patients who received first allogeneic hematopoietic stem cell transplantation in measurable residual disease-negative CR1. Bone Marrow Transplant. 2024.
Min G-J, Jeon Y-W, Kim TYoon, Kwag D, Kim B-S, Lee J, Lee JHyuk, Park S-S, Park S, Yoon J-H, et al. The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma. Sci Rep. 2023;13(1):17496.
Lee S-E, Yoon J-H, Shin S-H, Park G, Min C-K. Skin Graft-versus-host Disease Following Autologous Stem Cell Transplantation for Multiple Myeloma. Immune Netw. 2013;13(3):107-10.
Yim J, Park S-S, Lee J-M, Yoon J-H, Kim H-J, Min C-K. Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. Blood Res. 2023.
Kwag D, Cho B-S, Bang S-Y, Lee JHyuk, Min G-J, Park S-S, Park S, Yoon J-H, Lee S-E, Eom K-S, et al. Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis. Blood Cancer J. 2022;12(12):169.
Cho B-S, Min G-J, Park S-S, Shin S-H, Yahng S-A, Jeon Y-W, Yoon J-H, Lee S-E, Eom K-S, Kim Y-J, et al. WT1 measurable residual disease assay in AML who underwent allogeneic hematopoietic stem cell transplantation; optimal time points, threshold, and candidates. Biol Blood Marrow Transplant. 2019.